$NVCR NovoCure Ltd Insider Trading Week 30/2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NovoCure Ltd in week 30/2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 0.00 | 3,718 | 0 | 7,434 | |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 34.00 | 5,115 | 173,910 | 15,343 | |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 83.20 | 1,905 | 158,502 | 78,789 | 80.7 K to 78.8 K (-2.36 %) |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 83.30 | 3,718 | 309,709 | 80,694 | 77 K to 80.7 K (+4.83 %) |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 82.92 | 5,115 | 424,136 | 76,976 | 82.1 K to 77 K (-6.23 %) |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 34.00 | 5,115 | 173,910 | 82,091 | 77 K to 82.1 K (+6.64 %) |
| Aug 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Option Exercise | A | 83.30 | 10,412 | 867,320 | 10,412 | |
| Aug 01 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Grant | A | 0.00 | 6,002 | 0 | 852,465 | 846.5 K to 852.5 K (+0.71 %) |
| Aug 01 2019 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 83.30 | 5,206 | 433,660 | 5,206 | |
| Aug 01 2019 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Grant | A | 0.00 | 3,001 | 0 | 15,617 | 12.6 K to 15.6 K (+23.79 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 19.25 | 12,500 | 240,625 | 25,000 | |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 80.06 | 100 | 8,006 | 76,976 | 77.1 K to 77 K (-0.13 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 79.41 | 3,857 | 306,288 | 77,076 | 80.9 K to 77.1 K (-4.77 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 78.68 | 2,455 | 193,150 | 80,933 | 83.4 K to 80.9 K (-2.94 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 77.28 | 2,800 | 216,376 | 83,388 | 86.2 K to 83.4 K (-3.25 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 76.39 | 2,710 | 207,017 | 86,188 | 88.9 K to 86.2 K (-3.05 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 75.04 | 578 | 43,372 | 88,898 | 89.5 K to 88.9 K (-0.65 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 19.25 | 12,500 | 240,625 | 89,476 | 77 K to 89.5 K (+16.24 %) |